Sun Pharma Advanced Research (532872) Stock Overview
Engages in the research and development of pharmaceutical products in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
532872 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Sun Pharma Advanced Research Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹197.70 |
| 52 Week High | ₹289.00 |
| 52 Week Low | ₹108.20 |
| Beta | 0.66 |
| 1 Month Change | -15.96% |
| 3 Month Change | 21.92% |
| 1 Year Change | 40.96% |
| 3 Year Change | -11.74% |
| 5 Year Change | -28.27% |
| Change since IPO | 126.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| 532872 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -7.1% | -0.3% | -0.4% |
| 1Y | 41.0% | 16.1% | 4.6% |
Return vs Industry: 532872 exceeded the Indian Pharmaceuticals industry which returned 16.1% over the past year.
Return vs Market: 532872 exceeded the Indian Market which returned 4.6% over the past year.
Price Volatility
| 532872 volatility | |
|---|---|
| 532872 Average Weekly Movement | 9.4% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 3.6% |
Stable Share Price: 532872's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: 532872's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 279 | Anilkumar Raghavan | sparc.life |
Sun Pharma Advanced Research Company Limited engages in the research and development of pharmaceutical products in India and internationally. It develops Sezaby, a benzyl alcohol and propylene glycol free formulation of phenobarbital sodium injection for the treatment of neonatal seizures; SPARC-121, a novel topical agent for the treatment of Alopecia Areata; and SPARC-122, an anti-MUC1 ADC for treatment of multiple cancer indications. The company is also involved in the development of PDP-716 for treatment of open-angle glaucoma.
Sun Pharma Advanced Research Company Limited Fundamentals Summary
| 532872 fundamental statistics | |
|---|---|
| Market cap | ₹64.25b |
| Earnings (TTM) | ₹15.84b |
| Revenue (TTM) | ₹19.09b |
Is 532872 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 532872 income statement (TTM) | |
|---|---|
| Revenue | ₹19.09b |
| Cost of Revenue | ₹324.76m |
| Gross Profit | ₹18.77b |
| Other Expenses | ₹2.93b |
| Earnings | ₹15.84b |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 48.82 |
| Gross Margin | 98.30% |
| Net Profit Margin | 82.97% |
| Debt/Equity Ratio | 41.8% |
How did 532872 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/16 06:14 |
| End of Day Share Price | 2026/08/14 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sun Pharma Advanced Research Company Limited is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Pankaj Kadu | Axis Capital Limited |
| null null | Emkay Global Financial Services Ltd. |